Aktuellt
SENASTE
Redeye summarises its investment case on BioArctic. While we acknowledge that the company can seem binary, our conviction has grown in the past couple of months. We are encouraged by the clinical and regulatory progress and maintain our valuation at SEK 265 per share, base case.
LÄS MER
